<p>SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381</p>

Abstract

Background: Increasing evidence implies the participation of long non-coding RNAs (lncRNAs) in chemoresistance to cancer treatment. Their role and molecular mechanisms in breast cancer chemoresistance, nevertheless, are yet not considerably elucidated. In this work, we research the function of small nucleolar RNA host gene 15 (SNHG15) in cisplatin (DDP) resistance of breast cancer and uncover the underlying molecular mechanism. Methods: SNHG15 and miR-381 expression levels were detected using Quantitative realtime PCR (qRT-PCR) analysis. The functional roles of SNHG15 and miR-381 in breast cancer were determined using MTT assay and flow cytometry analysis. The effect of SNHG15 on miR-381 expression was determined using Luciferase reporter assay, RNA immunoprecipitation (RIP) assay and qRT-PCR analysis. Results: SNHG15 was found to be up-regulated in cisplatin resistant breast cancer tissues and cell lines. Breast cancer patients with high SNHG15 expression had a poor prognosis. SNHG15 silencing enhanced cisplatin sensitivity of MCF-7/DDP and MDA-MB-231/DDP cells. Additionally, SNHG15 could function as a miR-381 sponge. miR-381 overexpression could overcome cisplatin resistance. miR-381 knockdown countered SNHG15 knockdown-mediated enhancement of cisplatin sensitivity in MCF-7/DDP and MDA-MB-231/DDP cells. Besides, SNHG15 knockdown facilitated cisplatin sensitivity of cisplatin resistant breast cancer cells in vivo. Conclusion: In summary, SNHG15 knockdown overcame cisplatin resistance of breast cancer by sponging miR-381, providing a novel therapeutic target for breast cancer.

MicroRNA-381 inhibits bladder cancer pathogenesis through directly controlling BMI1 and triggering the Rho/ROCK signaling pathway defect

“…Similar trends have also been previously in miR-124-3p [22] and miR-203a [23]. As for miR-381, it has been particularly suggested to play critical functions in overcoming cisplatin resistance in breast cancer treatment [24][25][26].…”

<p>Long Non-Coding RNAs in Drug Resistance of Breast Cancer</p>

“…73 LncRNA SNHG15 is upregulated in MCF-7/DDP and MDA-MB-231/DDP cells, and knockdown of SNHG15 increases DDP sensitivity in BC cells by sponging miR-381. 74 LncRNA HCP5 is upregulated in MDA-MB-231/DDP cells and promotes DDP resistance by inhibiting the expression of PTEN; this effect has been observed in TNBC xenografts in vivo. 75…”

“…52-54 SNHG15 increases the sensitivity of BC cells to DDP by sponging miR-381. 74 CASC2 is upregulated in BC cells and sponges miR-18a-5p to enhance PTX resistance. 68 TINCR sponges miR-125b and promotes TZB resistance in HER-2+ BC cells.…”

<p>Long Non-Coding Small Nucleolar RNA Host Genes (SNHGs) in Endocrine-Related Cancers</p>

“…Additionally, SNHG15 knockdown enhances the cisplatin sensitivity of breast cancer cells by acting as a sponge for miR-381. 71 Moreover, bioinformatics analysis showed SNHG16 might be associated with the prognosis of breast cancer. 72,73 In particular, SNHG16 may interact with miR-30a to regulate the expression of ribonucleosidediphosphate reductase subunit M2 (RRM2) 74 and competitively bind miR-98 and the E2F Transcription Factor 5 (E2F5) 75 to promote the proliferation and invasion of breast cancer cells.…”